Fig. 5

PK-PD study of Pegmolesatide in healthy mice after single subcutaneous injection. A Changes in red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT%) in the serum of mice over time. Seventy-two 7–8-week-old BALB/c female mice were randomly divided into six groups of twelve mice each, and were treated with vehicle, Subcutaneous Injection (SC) injection; 0.08 mg/kg Pegmolesatide, SC injection; 0.16 mg/kg Pegmolesatide, SC injection; 0.08 mg/kg peptide dimer, SC injection; 0.16 mg/kg peptide dimer, SC injection; and 500 IU/kg ESPO3000, iv injection. Whole blood was collected from the orbit on day 4, 6, 8, and 14 after administration. B The concentration of Pegmolesatide in the serum of mice over time. Normal mice were injected with 0.08mpk Pegmolesatide under the skin. Blood samples were collected from the orbital blood of the mice at 0, 0.5, 2, 4, 8, 24, 48, 72, 96, 144, 192, and 336 h after administration. There was a total of 12 time points, with 3 mice at each time point. The average drug-time curve was drawn based on the measured blood drug concentration, and the pharmacokinetic parameters were estimated using a non-compartmental model to obtain the main pharmacokinetic parameters of the drug, in order to fully reflect the characteristics of drug distribution and elimination in mice